Advertisement
Canada markets closed

  • S&P/TSX

    21,642.87
    -97.33 (-0.45%)
     

  • S&P 500

    5,051.41
    -10.41 (-0.21%)
     

  • DOW

    37,798.97
    +63.86 (+0.17%)
     

  • CAD/USD

    0.7231
    -0.0022 (-0.31%)
     

  • CRUDE OIL

    85.36
    -0.05 (-0.06%)
     

  • Bitcoin CAD

    87,087.74
    -440.85 (-0.50%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,401.90
    +18.90 (+0.79%)
     

  • RUSSELL 2000

    1,967.48
    -8.23 (-0.42%)
     

  • 10-Yr Bond

    4.6590
    +0.0310 (+0.67%)
     

  • NASDAQ

    15,865.25
    -19.77 (-0.12%)
     

  • VOLATILITY

    18.40
    -0.83 (-4.32%)
     

  • FTSE

    7,820.36
    -145.17 (-1.82%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • CAD/EUR

    0.6808
    -0.0016 (-0.23%)
     
BREAKING:

$535B CANADA BUDGET PROJECTS $39.8B DEFICIT, AIMS TO RESTORE ECONOMIC FAIRNESS

It seeks to ease the housing and affordability crisis by making older, wealthier Canadians pay more

INVESTOR ALERT - Nektar Therapeutics (NKTR) - Bronstein, Gewirtz & Grossman, LLC Notifies of Class Action and Lead Deadline: October 18, 2019

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / October 11, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the Company") (NKTR) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Nektar securities between February 15, 2019 through August 8, 2019, both dates inclusive. Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/nktr.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) that the Company did not comply with current good manufacturing practices; (2) that, as a result, batches of NKTR-214 were not produced consistently and differed meaningfully; (3) that clinical results from PIVOT-02 differed based on the batch of NKTR-214 used in the study; (4) that, as a result, the PIVOT-02 study did not produce statistically significant results to support a finding of clinical benefit; and (5) as a result, Nektar's public statements were materially false and misleading at all relevant times.

If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/nktr or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss Nektar you have until October 18, 2019 to request that the Court appoint you as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

ADVERTISEMENT

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/562164/INVESTOR-ALERT--Nektar-Therapeutics-NKTR--Bronstein-Gewirtz-Grossman-LLC-Notifies-of-Class-Action-and-Lead-Deadline-October-18-2019